News for EyePoint Pharmaceuticals, Inc. (EYPT)

**media[578187]**

Mizuho Financial Group analysts reveal that the spending power of America's aging population, particularly those aged 75 and above, will significantly impact the market, unlocking a $1 trillion opportunity, termed

Americans over the age of 75 are expected to grow their spending by more than $2 trillion in the next 10 years, according to Mizuho.

**media[568255]**

U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Friday. Shares of Li Auto Inc. LI fell sharply in today's pre-ma...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ETCompany ParticipantsGeorge Elston - EVP and CFOJay...

Although the revenue and EPS for EyePoint Pharmaceuticals (EYPT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -56.10% and 21.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $11.6 million for Q4 2024, surpassing the estimated $11.09 million.Earnings Per Share (EPS): Reported at ($0.64) for Q4 2024, missing the estimated EP

”“ Enrollment exceeding expectations in DURAVYUâ„¢ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule ”“

”“ Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million ”“ ”“ Reported Quarterly Jornay PM® Net Revenue of $29

**media[552841]**

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. ( EYPT), a company committed to developing and commercializing innovative t

”“ Company presentation scheduled on Tuesday, March 4th at 9:10am ET ”“ ”“ EyePoint to provide enrollment update for ongoing DURAVYUâ„¢ Phase 3 pivotal pr

**media[542275]**

WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. ( EYPT), a company committed to developing and commercializing therapeutics

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,181,818 shares of EyePoint Pharmaceutical

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic macular edema or DME.